semaglutide naion NAION is a very rare side effect of semaglutide medicines - Semaglutide NAIONmeta-analysis They found a small but statistically significant increase in NAION risk Understanding the Potential Link Between Semaglutide and NAION

OzempicNAION Semaglutide, a popular medication widely used for managing type 2 diabetes and promoting weight loss, has recently been under scrutiny for a potential association with non-arteritic anterior ischemic optic neuropathy (NAION). This condition, characterized by a sudden loss of blood supply to the optic nerve, can lead to irreversible vision loss. While research is ongoing, understanding the current findings and the nuances of this potential risk is crucial for both patients and healthcare providers.

What is NAION?

NAION is defined as a sudden, painless loss of a part of vision in one eye, often accompanied by optic nerve swelling.作者：GR Natividade·2025·被引用次数：17—However, it was associated with nonarteritic anterior ischemic optic neuropathy (NAION). Meaning Future studies should implement standardized ... It occurs due to a disruption in blood flow to the optic nerve, leading to tissue damage. While various factors can contribute to its development, including age, vascular risk factors, and sleep apnea, emerging studies are exploring a possible link with certain medicationsOnce-weekly semaglutide doubles the five-year risk of ....

Semaglutide and the Increased Risk of NAION

Several studies and reports suggest a potential association between the use of semaglutide and an increased risk of NAION. These findings indicate that semaglutide users might experience a higher incidence of this eye condition compared to individuals not using the medication or those on other treatments.Use of semaglutide and risk of non‐arteritic anterior ischemic ... For instance, some research has shown that once-weekly semaglutide more than doubles the risk of NAION. Another study indicates that patients prescribed semaglutide had a higher risk of developing NAION compared to those on non-GLP-1 RA antidiabetes agents2025年6月6日—PRAC concludes eye conditionNAION is a very rare side effect of semaglutide medicinesOzempic, Rybelsus and Wegovy..

The magnitude of this risk can vary. Some reports suggest that for people with diabetes on semaglutide, there's *around four times the risk of NAION*, and for individuals with obesity on semaglutide, the risk is *more than seven times higher*. However, it is also noted that while the use of semaglutide is associated with an increased risk of NAION, the excess absolute risk is generally considered low1. JAMA Ophthalmology 研究 • 發現使用semaglutide的患者，發生NAION的風險較未使用者明顯升高。 ... 在糖尿病患者族群中，風險約增加4 倍；在肥胖族群中 .... In fact, regulatory bodies like the EMA have concluded that NAION is a very rare side effect of semaglutide medicines, potentially affecting up to 1 in 10,000 users. This implies that semaglutide treatment may be very rarely associated with NAION.

Factors Influencing Risk

The interplay between semaglutide and NAION is complex, and several factors might influence an individual's susceptibility. Research by CX Cai et al. suggests that the risk of NAION was higher among semaglutide users regardless of prior medication exposure when compared with empagliflozin. Furthermore, another study by E Simonsen et al.《眼科衛教-2》 前幾天「瘦瘦針恐致眼中風失明」的報導 ... investigated whether semaglutide increased the risk of NAION and observed that while the association exists, the excess absolute risk remains low. KY Chen et al. found that semaglutide use shows association with increased NAION risk, particularly with prolonged exposure and in patients with predisposing factors.

It's important to note that some studies have found conflicting resultsThe Effect of Semaglutide and GLP-1 RAs on Risk .... For example, NJ Abbass et al.作者：E Simonsen·2025·被引用次数：52—The use ofsemaglutidefor managing type 2 diabetes is associated with an increased risk ofNAIONcompared with the use of SGLT-2is. reported that there was no significant increase in risk of NAION or ION in patients taking semaglutide or GLP-1RAs compared to T2DM or high BMI controlsSemaglutide and NAION. However, other research, such as that by O Fazal, did find a small but statistically significant increase in NAION risk with semaglutideSemaglutide and NAION.

Related Concerns and Medications

The discussion around semaglutide and NAION also brings up related searches and concerns, such as NAION tirzepatide and NAION GLP1. As semaglutide is a GLP-1 receptor agonist, investigations into other drugs within this class, like exenatide, have also indicated an increased risk of NAION.1天前—具體案例：2025 年初的研究記錄了9 位在使用Tirzepatide 或Semaglutide後出現視力問題的病例，其中7 位呈現類NAION症狀（視神經盤水腫、視野缺損）。 爭議點 ... This broader look at GLP1 medications helps understand the potential class-wide effects.Once-weekly semaglutide doubles the five-year risk of ... Additionally, the mechanism behind this association, explored in searches like semaglutide NAION mechanism, is an active area of research, with ongoing efforts to understand how semaglutide might contribute to this condition.

While Ozempic NAION is a common search term, it's important to remember that semaglutide is the active ingredient in medications like Ozempic, Rybelsus, and Wegovy. Therefore, any risk associated with semaglutide would apply to these branded products.

Symptoms and Management

Understanding NAION symptoms is crucial. As mentioned, they typically include a sudden, painless loss of vision in one eye. If NAION is confirmed, treatment or cessation of certain medications, including semaglutide, might be considered作者：J Grauslund·2024·被引用次数：72—...semaglutide independently more than doubled the risk of NAION. Given the irreversible nature of NAION, it is important to acknowledge this .... This highlights the importance of open communication with healthcare providers about any visual changes experienced while on semaglutide作者：JT Hathaway·2024·被引用次数：263—This matched cohort study of 16 827 patients revealedhigher risk of NAION in patients prescribed semaglutidecompared with patients prescribed non–glucagon- .... Some studies, like the one by CC Chou, have explored the association between semaglutide and NAION over time, with specific numbers of patients developing NAION in both semaglutide and non-GLP-1RA groupsThe Effect of Semaglutide and GLP-1 RAs on Risk ....

Conclusion

The relationship between semaglutide and NAION is a developing area of medical research. While some studies point to an increased risk for semaglutide users, other findings suggest the risk is very rare and the absolute increase is low. The medical community continues to investigate the semaglutide NAION mechanism and gather more comprehensive data through studies like semaglutide NAION meta-analysis. Patients currently using semaglutide or considering it, especially those with underlying risk factors for NAION, should discuss their concerns with their ophthalmologist and prescribing physician. This collaborative approach ensures informed decision-making and proactive eye health management.